{"entity":{"id":"nct06802757","kind":"trial","name":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer","aka":["PRISM-TNBC"],"tldr":"A phase 2 trial of nab-paclitaxel, carboplatin and cyclophosphamide in triple-negative breast cancer, run by Shandong Cancer Hospital and Institute, now recruiting.","summary":"Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer is a phase 2, randomised interventional study registered as NCT06802757 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 72 participants, started 2025-05-01 and due to reach its primary completion in 2026-06-30. Interventions recorded: Posaconazole; Nab-paclitaxel; Carboplatin; Anthracycline; Cyclophosphamide; PD-1 inhibitors. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: \"first-confirmed TNBC;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06802757","url":"https://clinicaltrials.gov/study/NCT06802757"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["nab-paclitaxel","carboplatin","cyclophosphamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06802757","phase":"2","setting":"A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus PD-1 Inhibitors and Chemotherapy Versus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer","sponsor":"Shandong Cancer Hospital and Institute","enrolled":72,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06802757/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}